BioCryst Pharmaceuticals Inc. (BCRX) just scored a meaningful FDA approval that could make life easier for families dealing with a rare and frightening genetic disorder. On Friday, the FDA greenlit the company's New Drug Application for Orladeyo oral pellets, a once-daily preventive therapy for children aged 2 to under 12 with hereditary angioedema.

If you haven't heard of hereditary angioedema, consider yourself lucky. It's a rare genetic disorder that causes recurring episodes of severe swelling, and it doesn't wait until adulthood to show up. About 40% of patients experience their first attack by age 5, which means parents are often dealing with emergency swelling episodes in preschoolers.

Here's what makes this approval notable: Orladeyo is now the first and only targeted oral prophylactic therapy for HAE patients aged two and above. That "oral" part matters more than you might think when you're dealing with toddlers and young kids who aren't exactly enthusiastic about medical procedures.

The new pellet formulation looks like sprinkles and works like them too. Kids can pour it directly into their mouth and wash it down with water or milk, or you can sprinkle it over a spoonful of soft, non-acidic food. It's a practical solution for an age group where getting them to take medicine can be its own daily battle.

BioCryst already had an Orladeyo capsule formulation approved back in December 2020, but that version was limited to patients 12 years and older. This new approval fills a critical gap for younger children who've been living with fewer preventive options.

The FDA based its decision on positive interim data from the APeX-P clinical trial, which happens to be the largest trial to date evaluating long-term prophylactic therapy for HAE in patients 2 to under 12 years old. The trial's primary goal was to describe the pharmacokinetic parameters of berotralstat (that's the active ingredient in Orladeyo), while secondary objectives looked at safety, tolerability, and efficacy in pediatric patients.

The interim results told a reassuring story. Orladeyo was well tolerated across this young age group, showed a consistent safety profile, and delivered early and sustained reductions in monthly attack rates. Importantly, researchers didn't identify any new safety signals beyond what they'd already seen in previous adult and adolescent trials.

BioCryst isn't stopping at the U.S. border. The company has already filed applications for the oral pellet formulation with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. Additional regulatory filings are planned for other global territories, including Canada.

As for the stock, BioCryst shares were down 2.57% at $7.38 at the time of publication on Friday.